RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · Real-Time Price · USD
2.550
-0.110 (-4.14%)
At close: Apr 1, 2025, 4:00 PM
2.597
+0.047 (1.83%)
After-hours: Apr 1, 2025, 4:33 PM EDT
RedHill Biopharma Employees
RedHill Biopharma had 53 employees as of December 31, 2023. The number of employees decreased by 60 or -53.10% compared to the previous year.
Employees
53
Change (1Y)
-60
Growth (1Y)
-53.10%
Revenue / Employee
$69,943
Profits / Employee
-$569,321
Market Cap
3.27M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
RDHL News
- 14 days ago - RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation - PRNewsWire
- 20 days ago - RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results - PRNewsWire
- 4 weeks ago - RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum - PRNewsWire
- 5 weeks ago - RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties - PRNewsWire
- 2 months ago - RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer - PRNewsWire
- 2 months ago - RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published - PRNewsWire
- 4 months ago - Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development - PRNewsWire
- 4 months ago - RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court - PRNewsWire